To characterize the clinical and radiological evolution of anti-GABAAR encephalitis, including MRI dynamics, occurrence of relapses, long-term outcomes, and associated predictors, as well as to assess the potential of LMO5 antibodies as a biomarker for paraneoplastic etiology.
Approach:
Patient Identification: Retrospective identification of patients with anti-GABAAR encephalitis from a biorepository, including clinical information and serum/CSF samples.
Clinical Definitions: Inclusion criteria based on clinical picture and antibody detection; exclusion of patients with incomplete data or concurrent antibodies.
Data Collection: Clinical information collected through questionnaires covering demographics, comorbidities, neurological symptoms, and outcomes.
LMO5 Antibody Studies: Assessment of LMO5 antibodies using cell-based assays and Western blot techniques.
Statistical Analysis: Comparative analysis using Fisher exact test, Mann–Whitney U test, and logistic regression to identify predictors of relapse and outcomes.
Key Findings:
A total of 33 patients were identified with anti-GABAAR encephalitis, comprising 4 children and 29 adults.
GABAAR antibodies were detected in both serum and CSF in 25 of the 29 adult patients.
Tumors associated with anti-GABAAR encephalitis were identified in approximately 30% of cases.
Relapse was defined as the new onset or worsening of symptoms after a period of stabilization lasting at least 2 months.
Interpretation:
The presence of GABAAR antibodies in both serum and CSF indicates a systemic immune response that may contribute to the pathophysiology of anti-GABAAR encephalitis. The identification of tumors in about 30% of patients underscores the importance of oncological evaluation in this population. The study highlights the potential for LMO5 antibodies to serve as a biomarker for paraneoplastic syndromes, suggesting a need for further investigation into their role in diagnosis and management.
Limitations:
The retrospective nature of the study may introduce selection bias and limit the generalizability of the findings.
The sample size of 33 patients may not be sufficient to draw definitive conclusions regarding the predictors of relapse and outcomes.
The reliance on clinical questionnaires for data collection may lead to reporting bias and incomplete data.
The assessment of LMO5 antibodies was limited to specific assays, and further validation in larger cohorts is needed to establish their role as a biomarker.
Conclusion:
The findings suggest that anti-GABAAR encephalitis can have a significant impact on patient outcomes, with a notable rate of relapse and associated malignancies. The study emphasizes the need for comprehensive clinical management and monitoring for relapses, as well as the potential utility of LMO5 antibodies in understanding the paraneoplastic nature of some cases. Further research is warranted to explore the long-term implications and therapeutic strategies for affected individuals.
